Changes in Proliferation Kinetics of T Cells: A New Predictive Cellular Biomarkers for Early Rheumatoid Arthritis? by Justyna Pawłowska et al.
Changes in Proliferation Kinetics of T Cells:
A New Predictive Cellular Biomarkers
for Early Rheumatoid Arthritis?
Justyna Pawłowska & Żaneta Smoleńska &
Zbigniew Zdrojewski & Jacek M. Witkowski & Ewa Bryl
Received: 1 February 2012 /Accepted: 30 March 2012 /Published online: 25 April 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Objective It has been demonstrated that early treatment of
rheumatoid arthritis (RA) patients prevents further joint
damage and disability, but biomarkers enabling early RA
to be distinguished within the undifferentiated arthritis (UA)
cohort are still being sought.
Purpose The aim of the research was to study the pathome-
chanism of initiation and progression of UA→RA and to
find such new predictive biomarkers on the basis of func-
tional studies of the immune system.
Methods 55 patients with UA were enrolled into the study
and followed up for 2 years. The dynamic parameters of
proliferation of the peripheral blood CD4+ T cells were
recorded at the UA stage. During the follow-up study,
standard diagnostic procedures were performed to make
the final diagnosis. Comparison of the CD4+ T cell prolif-
eration parameters in the UA-RA and UA-non-RA patients
was conducted after the final diagnosis was established.
Results Our studies showed that the G0-G1 transition time,
the cell cycle duration, the number of cell divisions per divid-
ing CD4+ cells and the percentage of dividing CD4+ T cells
differed significantly between UA-RA and UA-non-RA
patients. Moreover, these proliferation parameters achieved
higher specificity and sensitivity in the detection of early RA
within UA patients compared to the routine serological tests
available.
Conclusion The proliferation parameters of CD4+ T cells
reflect central pathophysiological changes in RA and can be
used as new biomarkers for early RA diagnosis, which
would enable the international rheumatology recommenda-
tion to be achieved concerning the early diagnosis and
treatment of RA patients.
Keywords Early rheumatoid arthritis . undifferentiated
arthritis . Tcells . lymphocyte proliferation . predictive
biomarkers
Introduction
The term “undifferentiated arthritis” (UA) is applied to the
most common type of arthritis at the early stage when, in the
absence of current recommended diagnostic criteria, it cannot
be classified into the well-known clinical disease categories of
defined inflammatory rheumatic diseases [1]. At the stage
identified as UA, identification of the subset of patients des-
tined to develop rheumatoid arthritis (RA) - the most severe
and persistent form of rheumatic disease - is a challenge for
both clinicians and researchers. The new diagnostic approach
would allow disease-modifying anti-rheumatic drugs
(DMARDs) to be introduced as an early treatment strategy
[2]. The body of evidence has highlighted the effectiveness of
DMARDs in patients with early RA before the first radio-
graphic evidence of erosions, in preventing further joint dam-
age and disability [3]. In line with European League Against
Rheumatism/American College of Rheumatology recommen-
dation, the concept of a “window of opportunity” for the
treatment of the patients should be acted upon as early as
possible [4]. Many studies have shown that such a therapeutic
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window of opportunity may exist within only the first few
months of the disease [3]. The possible advantage of early
therapy underscores the need for a new diagnostic tool for
early diagnosis of such patients. On the other hand, clear
differentiation between early RA and other rheumatic diseases
at such an early stage (UA) still causes major difficulties for
rheumatologists. In fact, current diagnostic criteria have not
moved beyond describing the early symptoms of these dis-
eases as the UAwhich is clearly insufficient.
Emerging data show that not only is RA a local joint
disease, but it also involves impairment of the systemic im-
mune system, both central, (including bone marrow [5]), and
peripheral [6–9]. A relatively new concept describes prema-
ture senescence of peripheral CD4+ T cells in established RA
patients, demonstrated by, for example, reduced overall pro-
liferative capacity, shorter telomere length, decreased T-cell
receptor diversity [9] and decreased Klotho expression [7].
Benefiting from the technique of precise, numerical as-
sessment of multiple parameters of lymphocyte proliferative
dynamics developed in our laboratory and already shown to
detect differences between proliferation of T cells of healthy
young and elderly people [6], we decided to apply it as a
potential tool for early diagnostics of RA. Thus, the aim of
our study was to find out if specific features of lymphocyte
proliferation dynamics could be ascribed to RA and if they
could offer a good diagnostic approach for distinguishing
patients with early RA from those with other rheumatic
diseases, early in the course of the disease, as desired for
improvement of the early diagnosis according to the Euro-




Fifty five adult patients (50 women, 5 men) with peripheral
joints manifestation were enrolled in the study. Median
duration of their symptoms was 5 months. Patients included
into the study did not fulfill any of the existing classification
criteria for any specific rheumatic disease and were classi-
fied as UA based on the literature data. Patients with a
definitive diagnosis at baseline and with a documented
duration of symptoms more than 1 year were excluded from
the study, as well as patients with psoriatic skin manifesta-
tion at the beginning of the disease and patients with other
chronic inflammatory conditions or malignancies in the
medical history.
The study was approved by the local ethics committees of
Medical University of Gdańsk. All patients gave their writ-
ten informed consent.
Clinical Assessment
The clinical assessment was done first at the stage of UA.
Disease activity was measured by DAS28 based on the
number of swollen and tender peripheral joints, patients`
overall assessment by visual analogue scale (VAS) and
erythrocyte sedimentation rate (ESR) before any treatment
with DMARDs and/or glucocorticoids were introduced. Ad-
ditionally, 24 h before the clinical assessment patients had
not received any non-steroidal anti-inflammatory drugs or
paracetamol.
Patients were followed-up by the same rheumatologist from
1 to maximum 2 years, the final diagnosis was established
during that time. The design of study is shown on Fig. 1.
The final diagnosis was established according to the
following criteria, available during the study: RA - Ameri-
can College of Rheumatology 1987 criteria [10], psoriatic
arthritis - the classification criteria for Psoriatic Arthritis
[11]; group of spondyloarthropathies with peripheral joints
involvement including patients belong to either spondyloar-
thritis positive for HLA-B27 antigen or reactive arthritis
based on the European Spondylarthropathy Study Group
criteria [12]; primary Sjögren syndrome according to
American-European Consensus Group Classification crite-
ria [13], osteoarthritis - according to American College of
Rheumatology criteria [14]. High levels of antibodies
against thyreoglobulin and thyroid peroxidase after exclu-
sion of Sjögren syndrome were classified as polyarthralgia-
associated thyroiditis. When the definitive diagnosis after
the follow-up study was not established, patients were
Fig. 1 Perspective 2-year follow-up study design. Patients with UA
were enrolled into the study and followed up for to 2 years. The T-cell
proliferation parameters were recorded at the UA stage and before any
treatment with disease-modifying anti-rheumatic drugs (DMARDs)/or
glucocorticoids were introduced. Twenty four hours before the diag-
nostic procedure patients had not received any non-steroidal anti-
inflammatory drugs or paracetamol. During the follow-up study, stan-
dard diagnostic procedures were performed to make the final diagno-
sis. Comparison of the results from the immunological studies was
conducted after the final diagnosis – RA, non-RA was established
(UA-RA vs. UA-non-RA)
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classified as early UA. Patients who initially presented
features of RA, but who subsequently developed clinical
and serological characteristics of systemic erythematosus
lupus (SLE) were diagnosed as a rhupus syndrome, defined
as an “overlap syndrome” of systemic erythematosus lupus
(SLE) and RA with positive for RF and/or anti-CCP and
anti-double-stranded DNA antibodies (anti-dsDNA) [15].
Final diagnosis, especially of RA was supported by X-ray
and ultrasound joint examination.
The patients who developed RAwere eventually grouped
in UA-RA subgroup, while patients who developed other
form of rheumatic diseases were grouped as UA-non-RA
subgroup.
Laboratory Diagnostic Procedures
The laboratory diagnostic procedures were performed
according to the recommendation by standard routine pro-
cedures including: ESR, anti-CCP, RF, anti-nuclear (ANA-
Hep2 antibodies), SSA/Ro, SSB/La, anti-double-stranded
DNA antibodies (ds-DNA) and HLA-B27 antigen. RF was
determined by immunoturbidimetric assay (Abbott), anti-
CCP antibodies were determined by enzyme-linked immu-
noadsorbent assay ELISA (Imtec Immunodiagnostica
GmbH). ANA-Hep2 antibodies were measured by indirect
fluorescent antibody (Medipan GmbH) while HLA-B27 by
PCR electrophoresis kit (Medipan GmbH). Quantitative
analysis of antibodies: anti-SSA, anti-SSB, anti-dsDNA
antibodies was done by commercially available ELISA kits
(Euroimmun).
Ex Vivo Lymphocyte Study
The proportion and absolute number of peripheral leuco-
cytes and lymphocytes, as well as proportion and absolute
number of CD3+CD4+ ex vivo before proliferation analysis
were measured by flow cytometry, using fluorescently
tagged anti-CD3 and anti-CD4 monoclonal antibodies
(DAKO, Glostrup, Denmark).
Assessment of Peripheral Blood Lymphocyte Proliferation
Dynamics
Venous blood samples were collected at the first visit to
rheumatologist, before standard diagnostic procedure and
before any treatment with DMARDs and/or glucocorticoids
were introduced. Twenty four hours before the diagnostic
procedure patients had not received any non-steroidal anti-
inflammatory drugs or paracetamol.
The test was performed according to literature [16].
Briefly, peripheral blood mononuclear cells (PBMC) were
isolated by Histopaque™ flotation. PBMC were stained
with 10 μM carboxyfluorescein diacetate succinimidyl ester
(CFSE, Molecular Probes-Eugene, Oregon). CFSE-loaded
cells were suspended in RPMI 1640 supplemented with
10 % fetal bovine serum, 2 mM -glutamine, penicillin and
streptomycin (Sigma, St Louis, MO) and samples of 1×106
PBMC × ml−1 were stimulated with 0.2 μg immobilized
anti-CD3 antibody (OKT3, BD Biosciences Pharmingen,
San Diego, CA) in culture plates for up to 118 h, in 5 %
CO2 at 37°C. Cultured PBMC were collected at two time
points (72 and 118 h) and stained with monoclonal anti-
bodies against surface T-cells markers. Single parameter
histograms of CFSE staining intensity were generated for
T-cells subpopulation. Numbers of cells in each peak were
determined with the help of WinMDI™ v. 2.09 (J. Trotter,
the Scripps Research Institute, La Jolla, CA). The cell cycle
duration described as the length of a single cell division
[hour], the length of G0-G1 transition time [hour] defined as
the period from the onset of stimulation to the beginning of
the gap 1 (G1 phase) of the interphase (duration of pre-
division resting phase), the number of cell divisions per
dividing cells and the percentage of dividing cells calculated
as ratio of the values obtained after 72 and after 112 h of the
cell cultivation were calculated according to mathematical
formula [16]. The number of divisions calculated per divid-
ing cells is defined as the sum of divisions required to
produce the observed numbers of cells in all generations
divided by the sum of dividing cells while the percentage of
dividing cells is defined as cells that divided in response to
the stimulation, producing viable progeny at the end of
observation period.
Statistical Analysis
The differences between analyzed clinical and laboratory
parameters were evaluated between UA patients who
developed RA (UA-RA) and patients who developed
other rheumatic diseases (UA-non-RA) subgroups. The
significances of differences between quantitative variables
were calculated by U-Mann–Whitney test, while of those
observed between qualitative variables by test of differ-
ence between two structure factors. Correlations between
two quantitative variables were performed by Spearman`s
rang correlation test and presented by Spearman`s corre-
lation coefficients ρ.
All tabularized results are presented as medians with 25th
and 75th quartile, while graphical illustration (box-and-
whisker plots) included additionally the minima and maxi-
ma observed. Univariate logistic regression analysis was
performed to identify relevant variables for distinguishing
UA-RA from UA-non-RA subgroup. Then, multiple regres-
sion analysis was performed including only the significant
variables from the univariate logistic analysis. p<0.05 was
considered significant, while 0.10≥p>0.05 was considered
borderline statistical significant. Diagnostic test properties
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(sensitivity and specificity) were calculated for each prolif-
eration parameter and serological tests based on the final
diagnosis of UA cohort and additionally for the proliferation
parameters on the cut-off value evaluated based on receiver
operating characteristic curves (ROC). ROC was created for
the proliferation parameters while the cell cycle duration
time and the ratio of number of cell divisions and the ratio
of percentage of dividing cells were classified as a destimu-
lant value. Area under the curve (AUC) was additionally
calculated. Statistical analysis was performed using Statis-
tica 9 StatSoft Poland.
Results
Basic Clinical Characteristics at Baseline Divided
According to Final Diagnosis and Comparison
Between UA-RA and UA-non RA
During clinical 2-year prospective follow-up study of 55 UA
patients (Fig. 1), 50 (91 %) of them fulfilled the diagnostic
criteria for specific rheumatic disease including: RA, primary
Sjögren`s syndrome, psoriatic arthritis, polyarthralgia-
associated thyroiditis, spondyloarthritis positive for human
histocompatibility leukocyte B27 antigen (HLA-B27) anti-
gen, reactive arthritis, rhupus and osteoarthritis. Remaining 5
(9 %) of the patients did not fulfilled any specific criteria even
after 2 years of observation and was categorized as early UA.
10 female patients (18 %) developed RA during the time of
observation. Basic clinical characteristics at baseline were
compared between early RA (UA-RA) and patients who
developed other rheumatic diseases (UA-non-RA), divided
according to final diagnosis (Table I). The subgroups did not
differed in age or percentage of female patients. UA-RA
patients achieved only borderline statistically significant
higher disease activity score (DAS28) value than UA-non-
RA subgroup during the first visit (p00.09).
Immunological Characteristics of UA Patients Divided
According to Final Diagnosis and Comparison
Between UA-RA and UA-non RA
We compared immunological characteristics recorded in UA
patients between UA-RA and UA-non-RA subgroups divid-
ed according to final diagnosis. We did not disclose statis-
tical significance differences in number of lymphocytes
between UA-RA and UA-non-RA patients. We showed
differences between percentages of positive anti-cyclic
Table I Basic clinical, labora-
tory and immunological differ-
ences between UA patients
subgroups divided according to
final diagnosis
a The differences between quan-
titative variables were calculated
by U-Mann–Whitney test,
while between qualitative varia-
bles by test of difference
between two structure factors
VAS- visual analogue scale,
ESR-erythrocyte sedimentation
rate, DAS – disease activity
score, RF - rheumatoid arthritis,
anti-CCP - anti-cyclic citrulli-
nated proteins ANA-antinuclear
antibodies
UA-RA (n010) UA-non-RA (n045) p a
Basic characteristic
Age, years, median (IQR) 54 (46–57) 46 (40–54) 0.169
Gender, number of females/men 10/0 40/5 0.136
Activity components
Number of tender joints, median (IQR) 7 (5–11) 6 (3–10) 0.380
Number of swollen joints, median (IQR) 4 (1–6) 2 (1–5) 0.360
VAS score by patients, median (IQR) 6.5 (6–7) 5.0 (4–6) 0.067
ESR, [mm/hour], median (IQR) 25 (22–48) 22 (11–35) 0.335
DAS28, median (IQR) 5.31 (4.30–5.97) 4.54 (3.38–5.33) 0.093
Immunological characteristic
Absolute number of leucocytes
[g/L],median (IQR)
6.55 (4.27–8.31) 6.37 (4.82–7.84) 0.679
% of lymphocyte, median (IQR) 30.00 (27.40–37.13) 29.75 (21.25–35.85) 0.464
Absolute number of lymphocyte
[g/L], median (IQR)
1.84 (1.55–2.12) 1.79 (1.31–2.12) 0.631
% of CD3+CD4+, median (IQR) 58.41 (46.90–63.87) 60.81 (55.91–65.81) 0.270
Absolute number of CD3+CD4+
[g/L], median (IQR)
0.97 (0.78–1.32) 0.96 (0.79–1.38) 0.887
RF, positive, % 80 % 43 % 0.078
anti-CCP, positive, % 80 % 33 % 0.025
ANA-Hep2, positive, % 0 % 49 % -
Proliferation dynamics parameters
Cell cycle duration [h] 20.36 (19.45–24.89) 30.73 (27.03–37.31) <0.001
G0-G1 transition time [h] 32.76 (27.64–42.39) 0.5 (0–17.89) <0.001
Ratio of number of cell divisions 0.67 (0.61–0.84) 0.87 (0.82–0.94) <0.001
Ratio of percentage of dividing cells 0.73 (0.68–0.82) 0.95 (0.88–0.98) <0.001
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citrullinated proteins antibodies (anti-CCP) patients between
the subgroups. Basic immunological characteristic for en-
rolled patients are shown in Table I.
Differences in CD4+ Lymphocyte Proliferation Dynamics
Between UA-RA and UA-non-RA Subgroups
Differences in CD4+ lymphocyte proliferation dynamics
between UA-RA and UA-non-RA subgroups were indicated
(Table I). The proliferation parameters differed significantly
(p<0,001) between UA-non RA and UA-RA patients re-
garding the cell cycle duration (Fig. 2a), the G0-G1 transi-
tion time (Fig. 2b), the ratio of number of cells divisions per
dividing cells (Fig. 2c) and the ratio of percentage of
dividing cells (Fig. 2d). The ratio of number of cell divisions
per dividing cells and the ratio of percentage of dividing
cells were characterized by the higher diagnostic test prop-
erties than each of the parameters alone (not shown). The
highest sensitivity and specificity of early RA detection
were indicated for the proliferation biomarkers, compared
to the laboratory serological tests performed at standard
diagnostics (Table II).
Identifying Relevant Variables Distinguishing UA-RA
from UA-non-RA Subgroups
Among all considered factors included: age, gender, compo-
nent of disease activity, diagnostic results, the proliferation
Fig. 2 Comparison of the proliferation dynamics parameters between
UA-RA and UA-non-RA patients. Each of the calculated proliferation
parameters differed significantly between the subgroups divided
according to the final diagnosis – RA and non-RA. (a) Cell cycle
duration. (b) G0-G1 transition time. (c) Ratio of number of cell divi-
sions. (d) Ratio of percentage of dividing cells. The cell cycle duration
described as the length of a single cell division [hour], the length of
G0-G1 transition time [hour] defined as the period from the onset of
stimulation to the beginning of the gap 1 (G1 phase) of the interphase,
the ratio of number of cell divisions defined as the sum of divisions
required to produce the observed numbers of cells in all generations
divided by the sum of dividing cells and the ratio of percentage of
dividing cells defined as cells that divided in response to the stimula-
tion, and were calculated according to the mathematical formula. The
results are presented in box-and-whisker plots using medians and 25th
and 75th quartile with whiskers to the minima and maxima of the data.
* - statistical significance (p<0.001) using U-Mann–Whitney test
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parameters, we identified relevant variables, which were
included in the multiple regression analysis. Neither age,
gender nor the disease activity factors possessed signif-
icant predictive power. Only the proliferation parame-
ters, anti-CCP and rheumatoid factor (RF) positivity
allowed distinguishing between UA patients destined to
develop of RA from the non-RA subgroup with high
statistical significance. Among the relevant variables,
only the G0-G1 transition time and the cell cycle dura-
tion were significantly strong parameters for early RA
distinguish (p<0.05) as well the ratio of number of cell
divisions per dividing cells and the ratio of percentage
of dividing cells (p00.09). The highest values of AUC
were recorded for the G0-G1 transition time and the cell
cycle duration (Fig. 3).
Correlation Between the Proliferation Dynamics Parameters
and Disease Activity in UA-RA Subgroup
In order to find out if the proliferation parameters
associate with severity of RA we correlated each of
the parameter with DAS28 values assessed at the stage
of UA. In subgroup of UA-RA we indicated that there
was a statistical significant positive correlation between
the G0-G1 transition time and DAS28 values (Spear-
man`s correlation coefficient ρ00.44, p<0.05). The op-
posite correlation was showed for the cell cycle duration
and DAS28 values, but this correlation did not reach
statistical significance (Spearman`s correlation coeffi-
cient ρ0− 0.23, p>0.05). Neither the ratio of number
of cells divisions per dividing cells nor the ratio of
percentage of dividing cells correlate with DAS28 val-
ues (accordingly Spearman`s correlation coefficients ρ0
0.08 and ρ00.02, respectively).
Discussion
Firm diagnosis of RA obtained prior to the onset of severe
disability and irreversible morphological damage to cartilage
Table II Diagnostic test efficacy of RF, anti-CCP and the proliferation parameters in prediction of early RA
Laboratory parameter AUC (95 % CI) specificity, % (95 % CI) sensitivity, % (95 % CI)
Standard serological test
RF - 56.3 (39.3–71.8) a 70.0 (39.7–89.2) a
Anti-CCP - 66.7 (52.1–78.6) a 80.0 (49.0–94.3) a
ANA-Hep2 - 51.1 (37.1–64.9) a 4.5 (5.0–32.1) a
Proliferation parameters
Cell cycle duration 0.948 (0.888–1.000) 92.5 (80.1–97.4) b 80.0 (49.0–94.3) b
G0-G1 transition time 0.944 (0.876–1.000) 89.0 (75.9–95.4) b 95.5 (67.9–99.5) b
Ratio of number of cell divisions 0.848 (0.713–0.982) 97.5 (87.1–99.6) b 60.0 (31.3–83.2) b
Ratio of percentage of dividing cells 0.818 (0.703–0.932) 74.1 (58.9–85.1) b 95.5 (67.9–99.5) b
Data is presented as 95% confidence interval
a The classification parameters were calculated after final diagnosis was established
b The classification parameters were calculated after final diagnosis was established based on the cut-off value evaluated based on ROC plot
AUC: area under the curve, RF: rheumatoid arthritis, anti-CCP: anti-cyclic citrullinated proteins, ANA: antinuclear antibodies
Fig. 3 Receiver operating characteristics curves of the proliferation
parameters. In order to compare diagnostic efficacy of the proliferation
parameters for distinguish early RA among UA patients, ROC plot was
created. The proliferation parameters achieved high AUC values
wherein the G0-G1 transition time and the cell cycle duration were
the most significantly strong predictive biomarkers for prediction of
UA→RA progression. (1) G0-G1 transition time. (2) Cell cycle dura-
tion time. (3) Ratio of number of cell divisions per dividing cells. (4)
Ratio of %percentage of dividing cells. (5) Regarding line. The cell
cycle duration, the ratio of number of cell divisions and the ratio of
percentage of dividing cells were presented as a destimulant variables
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and bone is of the utmost importance [17]. From onwards
1987 the limitations of the American College of Rheumatol-
ogy criteria for early RA diagnosis resulted in the establish-
ment of new classification criteria by European League
Against Rheumatism/American College of Rheumatology
experts in 2010 with the aim of identifying patients with
inflammatory arthritis who are at high risk of developing
persistent and erosive RA [18]. These criteria are still classi-
fication rather than diagnostic criteria, and therefore diagnos-
tic methods which could be termed as biomarkers for such an
early distinction are still missing.
Among the available laboratory markers for RA are the
recommendations of the 2010 European League Against
Rheumatism/American College of Rheumatology which in-
clude, in addition to RF, anti-citrullinated peptide antibodies
(ACPA), mainly represented as anti-CCP antibodies. Many
results have been obtained which confirm that anti-CCP
antibodies have higher specificity and sensitivity than RF
in the diagnosis of RA. On the other hand, a number of
reports have shown great disproportion in the sensitivity and
specificity calculations of serological markers in terms of
providing an accurate prognosis of early RA. In addition,
the results in diagnosis and prediction of early RA have
been sharply contradictory and differed from those for
established RA [19–21]. According to the published results
the sensitivity of anti-CCP antibodies in early RA ranges
from 39 to 61 %, while the specificity ranges from 93 to
98 % [20, 21]. Similarly the RF marker showed a sensitivity
of 31 to 54 % with a specificity from 86 to 93 % [20–22].
The great disparity between the results for sensitivity and
specificity is mainly due to the discrepancies in methodolo-
gy for the kits that are commercially available and differ-
ences in set cut-off values and test generation. Despite the
higher specificity of the anti-CCP test compared to RF in the
diagnosis of early RA, RF still seems to be useful in diag-
nosis. Ursum et al. showed that RF may be present in
patients with RA, the serological negative of anti-CCP anti-
bodies [23]. However, RF and anti-CCP antibodies are
detected even in subjects with non-rheumatic disease [23,
24]. One of the severe limitations of anti-CCP antibodies
was demonstrated by Ioan-Facsinay et al. [25], who showed
that anti-CCP antibodies as measured by the most frequently
performed test using the ELISA second generation set of the
test and specific anti-CCP antibodies are largely cross-
reactive with many epitopes, which outweighs their hetero-
geneity. These results hardly make either marker acceptable
as an early RA predictor.
Our study revealed that 80 % of early RA patients were
positive for anti-CCP antibodies and 70 % for RF, but that
antibodies were very frequently presented also in other
subgroups of very early rheumatic diseases, which de-
creased their predictive value. The specificities of the RF
and anti-CCP were therefore much lower for our patients
than those cited above. It is important to stress that there are
many limitations of calculations concerning the diagnostic
accuracy of the markers, including differences between
studies in terms of the population analyzed, the frequent
lack of clear definition of the participation of those with
disease (e.g. diseases duration), differences in the methods
of validating the diagnostic accuracy or lack of internal
standardization [26]. In line with this, many of the calcula-
tions of the diagnostic accuracy of the anti-CCP antibodies
and RF markers are available are calculated on the basis of
patients with established and early rheumatic disease and
with inclusion of healthy subjects. The specificity of the
markers in such studies may therefore be underestimated
in comparison with that calculated here and in the studies
which included only very early arthritis group [26, 27]. In
our study the specificity and sensitivity calculations for anti-
CCP antibodies, RF, ANA-Hep2 and proliferation parame-
ters are based only on very early UA-subgroups that were
characterized by very similar clinical presentation, while the
healthy cohort was not included.
In addition, it should be pointed out that citrullination
was observed also during unrelated inflammation and apo-
ptosis, which emphasized that the presence of citrullinated
proteins at the early stage of immune diseases may not be
specific for RA only [28]. This is in keeping with the
marked presence of anti-CCP antibodies demonstrated by
us among UA patients at the earliest stage of disease. The
other possible explanation of the low specificity of anti-CCP
antibodies and RF in our patient cohort in comparison with
other published results might be the relatively large number
of patients with primary Sjögren syndrome, psoriatic arthri-
tis and thyroid autoimmune diseases developed from our
initial group of patients with UAwho manifested arthritis at
the beginning of the follow-up study. The presence of RF as
well as anti-CCP antibodies in other rheumatic patients,
especially those with psoriatic arthritis and systemic eryth-
ematosus lupus (SLE), has been confirmed by other
researchers [29, 30]. On the other hand, our study did not
include patients with other forms of rheumatic diseases such
as Wegeners`s granulomatosis or viral- induced arthritis
included in other cited studies.
The low diagnostic power of the serological markers
available and recommended was confirmed in our study in
the regression analysis, which showed that the proliferation
parameters are stronger factors for distinguishing the UA-
RA group from the UA-non-RA group. Despite the obser-
vation that some disease activity components differed in UA
patients developing other forms of rheumatic disease, nei-
ther the disease activity (DAS28) parameter nor its compo-
nents were useful for distinction of the UA-RA from the
UA-non-RA subgroup.
Therefore, we undertook the challenge of meeting the
need for more sensitive and specific predictors of UA →
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RA transition. Our idea came from the hypothesis
concerning the premature immunosenescence of CD4+ T
cells in RA patients. Having established a platform to study
proliferative dynamics of these cells including previously
unavailable parameters before [6], we decided to check if
any of these could serve as new biomarkers for early RA
with possibly higher predictive power than anti-CCP and
RF.
Our results confirmed that the proliferation status of CD4+
T cells in early RA patients reflects their (suggested) prema-
ture immunosenescence. We have shown before that the cell
cycle of CD4+ cells of healthy elderly donors stimulated with
anti-CD3 and anti- CD28 antibodies is significantly shorter,
while the G0-G1 transition time is extended compared to that
found in young people [6]. Thus, different characteristics of
the dynamic parameters of the cell cycle in early UA-RA
patients and in non-UA-RA patients shown in our study
confirm the immunosenescence hypothesis of RA [9, 31]. In
addition, our preliminary observation showed that patients
from UA group who developed RA, and did not achieved
remission after DMARDs treatment for 6 months – 1 year, still
had prolonged G0-G1 transition time and shorter the length of
the cell cycle duration (own observation).
Important issue which remains to be discussed is in
particular whether the T cells alterations we have exposed
vary between the genders. Compelling evidence obtained by
many authors demonstrates that there is a significant female
excess for the major connective tissue autoimmune disease
[32]. In our study only female patients developed RAwhich
strongly confirms this trend. Nevertheless, in the group of
UA-non-RA we did not show any differences in all prolif-
eration parameters between male and female patients, what
might suggest that the biomarkers proposed by us did not
change depending the genders.
The caveat that must be attached to our study is that a
relatively small group of patients was enrolled in the inves-
tigation. However, the intensive laboratory work and 2 years
of follow-up from the UA stage to the final diagnosis for 55
patients is, in our opinion, a sufficient basis for suggesting
the new biomarkers in particular as the parameters proposed
were the most significant of various factors, including sero-
logical markers and disease activity features, in distinguish-
ing RA from early UA at the outset of the diagnostic
procedure very early in the course of the disease. The
method underwent the process of validation and laboratory
verification.
Conclusions
We have thus proposed, for the first time, a set of new
biomarkers related to the proliferation kinetics of CD4+ T
cells for highly specific and sensitive prediction as to which
early UA patients will progress to RA. In addition to the
high degree of sensitivity and specificity of the new bio-
markers, the proliferation parameters reflect central patho-
physiological changes in early RA, emphasizing the value
of the new biomarkers in comparison with RF and anti-CCP
antibodies.
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